ImageneBio to Participate in Leerink Global Healthcare Conference
ImageneBio (NASDAQ: IMA) will participate in the 2026 Leerink Global Healthcare Conference in Miami, March 8-11.
Rhea-AI Summary
ImageneBio (NASDAQ: IMA) will participate in the 2026 Leerink Global Healthcare Conference in Miami, March 8-11. Management will join a fireside chat on March 10 at 3:00 PM EST and hold one-on-one meetings. A webcast will be available and archived for 90 days on the company events page.
Positive
- None.
Negative
- None.
Details
News Market Reaction – IMA
On Feb 26, the day this news came out, IMA closed 1.64% above the previous close.
Data tracked by StockTitan Argus for the Feb 26 session.
Key Figures
- Conference dates
- March 8–11, 2026
- Leerink Global Healthcare Conference timing
- Fireside chat date
- Tuesday, March 10
- ImageneBio scheduled presentation date
- Fireside time
- 3:00 PM EST
- Scheduled time for ImageneBio’s fireside chat
- Webcast archive period
- 90 days
- Duration webcast remains available on IR events page
Historical Context
-
Named new Chief Medical Officer to lead clinical organization and ADAPTIVE trial.
-
Reported Q3 results, cash of $142.6M, $75M placement, and IMG-007 progress.
-
Announced participation in multiple Q4 2025 investor conferences with webcasts.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA, “Imagene,” or the “Company”), today announced management will participate in a fireside chat and hold one-on-one meetings at the 2026 Leerink Global Healthcare Conference taking place March 8-11 in Miami, Florida.
Fireside Date: Tuesday, March 10
Time: 3:00pm EST
Webcast: Linked here and archived for 90 days on events page on the Imagene IR website
About ImageneBio, Inc.
Imagene is a clinical-stage biotechnology company dedicated to developing therapeutics for patients with immunological, autoimmune and inflammatory diseases with differentiated clinical profiles. The Company’s program, IMG-007, is a receptor targeting, nondepleting anti-OX40 monoclonal antibody with multiple differentiating features. Imagene has completed Phase 1b/2a clinical trials of IMG-007 in both atopic dermatitis and alopecia areata and is currently conducting a Phase 2b clinical trial of IMG-007 in patients with moderate-to-severe atopic dermatitis. For more information, please visit www.imagenebio.com.
Investor and Media Contact:
ir@imagenebio.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.